Floatz logo

10 assets in Endometrial Endometrioid Adenocarcinoma

Therapeutic assets addressing Endometrial Endometrioid Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Ipilimumab
Endometrial Endometrioid Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Nivolumab
Endometrial Endometrioid Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Tazemetostat
Endometrial Endometrioid Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Tirzepatide
Endometrial Endometrioid Adenocarcinoma
UNC Lineberger Comprehensive Cancer CenterP2CCC (53)
Adriamycin
Endometrial Endometrioid Adenocarcinoma
National Cancer Institute (NCI)P1CC (43)
Amt-151
Endometrial Endometrioid Adenocarcinoma
Multitude Therapeutics Inc.P1CC (43)
Atezolizumab
Endometrial Endometrioid Adenocarcinoma
UNC Lineberger Comprehensive Cancer CenterP1CC (43)
Bet Bromodomain Inhibitor Zen-3694
Endometrial Endometrioid Adenocarcinoma
National Cancer Institute (NCI)P1CC (43)
Tuvusertib
Endometrial Endometrioid Adenocarcinoma
National Cancer Institute (NCI)P1CC (43)
Dordaviprone
Endometrial Endometrioid Adenocarcinoma
UNC Lineberger Comprehensive Cancer CenterP1C (39)